09.19.11
Spinal Restoration Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for claims concerning the delivery device and method of use of the Biostat System for the treatment of discogenic low back pain.
“We believe that the design of the Biostat System overcomes significant hurdles to safe delivery of biologic materials to the intervertebral disc,” said Gary Sabins, president and CEO of Spinal Restoration. “The allowance of these claims strengthens Spinal Restoration’s broad intellectual property portfolio and helps to fortify our leadership position in the field of intradiscal biologic therapies.”
The Biostat System combines the Biostat Biologix Fibrin Sealant, a human-derived, biologic tissue sealant, and the Biostat Delivery Device, an application system designed for safe delivery of biologic materials to the intervertebral disc.
Spinal Restoration became the first company to initiate a Phase III study of a biologic therapy for discogenic low back pain in March 2010. The Phase III study will include 260 patients, and is currently enrolling subjects at 20 centers across the United States.
“We believe that the design of the Biostat System overcomes significant hurdles to safe delivery of biologic materials to the intervertebral disc,” said Gary Sabins, president and CEO of Spinal Restoration. “The allowance of these claims strengthens Spinal Restoration’s broad intellectual property portfolio and helps to fortify our leadership position in the field of intradiscal biologic therapies.”
The Biostat System combines the Biostat Biologix Fibrin Sealant, a human-derived, biologic tissue sealant, and the Biostat Delivery Device, an application system designed for safe delivery of biologic materials to the intervertebral disc.
Spinal Restoration became the first company to initiate a Phase III study of a biologic therapy for discogenic low back pain in March 2010. The Phase III study will include 260 patients, and is currently enrolling subjects at 20 centers across the United States.